SEF Speaker

Stéphane Epelbaum

Associate Vice President, International Business Unit, Eli Lilly and Company
Stéphane Epelbaum

Dr. Stéphane Epelbaum is a board-certified neurologist witha PhD in neuroscience. He played a pivotal role in shifting the concept of Alzheimer’s disease (AD) from unspecific dementia to a precise clinical-biological entity. He has participated in over 30 clinical trials including Aramis Lab, a brain data science lab. Dr. Epelbaum has authored over 100 articles on Alzheimer’s disease and related disorders, emphasizing timely and accurate diagnosis and innovative therapeutic options.

As a member of the International Working Group, Dr. Epelbaum notably contributed to the guidelines and co-authored a consensus article on preclinical Alzheimer’s disease with the National Institute on Aging and Alzheimer Association. In 2018, he was honored with the French Foundation Alzheimer's Prize for his outstanding clinical research. Since 2021, he has led the medical affairs neurology team in the international business unit of Eli Lilly and Company, focusing on closing clinical care gaps in neurological disorders.

Stéphane Epelbaum

This Speaker's Events

Sign up to stay up-to-date on the latest SEF news.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
For more information, contact [email protected]
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.